RESEARCH ARTICLE

EPIDEMIOLOGICAL, CLINICAL AND ECHOCARDIOGRAPHIC FEATURES OF HEART FAILURE IN MOROCCO

A. Maliki Alaoui¹, Y. Fihri¹, A. Ben El Mekki¹, H. Bouzelmat¹, I. Asfalou¹, N. Mouine¹, A. Benyass¹, L. Lahlou², R. Razine² and R. Abouqal²

1. Cardiology Department of the Military Training Hospital of Mohamed V, Rabat, Morocco.
2. Laboratory of Epidemiology and Clinical Research, Mohamed V university, Rabat, Morocco.

Manuscript Info

Abstract

Heart failure (HF) is a major public issue taking an epidemic dimension globally. Its incidence is continuing to rise because of a growing and aging population. We held a cross-sectional retrospective study in the cardiology department of Mohamed V military teaching hospital of Rabat in Morocco from September 2019 to September 2021, including 104 patients admitted with HF. The mean age was 68.5 ± 10.3 years. Hypertension and diabetes mellitus are the most common risk factors. HF with reduced ejection fraction represents about 49%. Forty-four percent had dilated cardiomyopathy. Ischemic heart disease is the first cause of HF.

Corresponding Author: - Amine Maliki Alaoui
Address:- Department of Cardiology, Mohamed V Training Military Hospital, University of Mohammed V, Rabat, Morocco.
This paper aims to study the epidemiological, clinical and echocardiographic features of heart failure through a retrospective study carried out in the cardiology department of Mohamed V military teaching hospital of Rabat in Morocco.

Patients and Methods:
This is a descriptive cross-sectional study carried out in the cardiology department of Mohamed V military teaching hospital of Rabat. The study enrolled 104 patients who were admitted with decompensated congestive heart failure during the period from September 2019 to September 2021.

All included patients were subjected to complete and detailed medical history, thorough physical examination, laboratory investigations, resting standard 12 leads electrocardiogram, chest X-ray, trans-thoracic echocardiography, and eventually coronary angiography.

Statistical analysis of results was performed using JAMOVI 1.6.23 software.

Results:
1. baseline characteristics:
The study included 68 males and 36 females, aged between 55 and 86 years (mean = 68.5 ± 10.3 year). Fifty-three percent were hypertensives, 50% had a history of DM, 32.7% were smokers, 23% were obese (BMI > 30), 25% had dyslipidemia, 34% had a history of ischemic heart disease. (table 1)

Table 1: Baseline characteristics of the study population:

| Characteristics | Values (N = 104) |
|-----------------|-----------------|
| Age (years)#    | 68.5 ± 10.3     |
| Sexe§           |                 |
| male            | 68 (65.4)       |
| Female          | 36 (34.6)       |
| DM§             | 52 (50)         |
| HTN§            | 56 (53.8)       |
| Dyslipidemia§   | 26 (25)         |
| Obesity§        | 24 (23.1)       |
| Smoking (current)§ | 34 (32.7)       |

# expressed in mean ± SD, § expressed in number (percentage), HTN: arterial hypertension, DM: diabetes mellitus.

2. clinical and electrical features:
Sixty-two percent of the patient presented with HF stage III-IV and 38% were NYHA I-II. The average heart rate was 94.5 ± 28 bpm. The mean of the systolic blood pressure was 119 ± 21.5 mmHg for the systolic and 68.9 ± 2.5 mmHg for the diastolic. All patients had 12 leads ECG, the findings are shown in figure (1).
AF: atrial firlillation  
LVH: left ventricular hypertrophy  
LAH: Left atrium hypertrophy  
LBBB: Left bundle branch block  
PVCs: premature ventricular contractions  
PACs: premature atrial contractions  
1st °AVB :1st degree atrio-ventricular block

3.Echocardiography :
All patients had a full echo evaluation which allows to categorize the patients according to the ejection fraction: 48.9% had a Heart failure with reduced ejection fraction (HFrEF), 33.3% with preserved EF (HFpEF), and 17.8% with midly reduced ejection fraction (HFmrEF) (figure 2). The details are shown in table 2.

Figure 1:- The main ECG abnormalities observed in HF in the study population.

Figure 2:- The distribution of the different ranges of fraction ejection in the study population.
Table 2: Echocardiographic features of the study population:

| Characteristics               | Values (N = 104) |
|-------------------------------|------------------|
| DCM§                          | 38 (44.2)        |
| LVEF#                         | 42.2 ± 15.1      |
| EDD#                          | 54.7 ± 12        |
| ESD#                          | 42.1 ± 12.9      |
| WMA§                          | 70 (76.1)        |
| Significant valvulopathy§     | 22 (23.4)        |
| Dilated LA§                   | 80 (87)          |
| LA surface#                   | 25.5 ± 7.33      |
| SPAP#                         | 43.7 ± 18.7      |
| Elevated LVFP§                | 42 (53.8)        |

#expressed in mean ± SD, §expressed in number (percentage), DCM: dilated cardiomyopathy, LVEF: left ventricular ejection fraction, EDD: end diastolic diameter, ESD: end systolic diameter, WMA: wall motion abnormalities, LA: left atrium, SPAP: systolic pulmonary artery pressure, LVFP: left ventricle filling pressure

Using logistic regression in univariate and multivariate analysis we tried to find a statistical association between the different cardiovascular risk factors and the evolution of heart disease to HF with reduced ejection fraction. Male sex and hypertension are the two characteristics associated with HFrEF (p-value <0.05). (Table 3)

Table 3: The statistical association between risk factors and HFrEF.

| Independents variables | Univariateanalysis | Multivariateanalysis |
|------------------------|--------------------|----------------------|
|                        | Beta               | IC 95%               | p       | Beta     | IC à 95%     | p       |
| Age                    | -0.007             | 0.937 ; 1.05        | 0.78    | -0.0291  | -0.9085 ; 1.038 | 0.043 |
| Sex:                   |                    |                      |         |          |                      |         |
| Male - Female          | -1.311             | -2.601 ; 0.0210      | 0.27    | -2.1006  | 0.0165 ; 0.910     | 0.04   |
| DM                     | 0.455              | 0.484 ; 5.13        | 0.45    |          | 0.1824 ; 4.201     | 0.86   |
| HTN                    | 1.118              | 0.968 ; 11.13       | 0.056   | 1.4630   | 0.8728 ; 21.370    | 0.033  |
| Dyslipidemia           | 0.397              | 0.391 ; 5.65        | 0.56    | 0.0455   | 0.1758 ; 6.231     | 0.96   |
| Obesity                | 0.677              | 0.485 ; 7.99        | 0.34    | 0.2520   | 0.2075 ; 7.976     | 0.78   |
| Smoking                | -1.245             | 0.0276 ; 3          | 0.29    | 0.641    | 0.0878 ; 41.085    | 0.68   |

HTN: arterial hypertension, DM: diabetes mellitus.

Discussion:
Heart failure is a clinical syndrome resulting from impaired diastolic filling or systolic ejection of the cardiac ventricles [4]. It is the most common cardiovascular condition, reaching about 10% of subjects over the age of 80. Its frequency is increasing on the one hand because of the aging of the population, but also because of better management of certain cardiovascular pathologies such as myocardial infarction, arterial hypertension, valvulopathies, rhythm and conduction disorders, without however curing them [5,6].

HF is a rapidly growing public health problem with an estimated prevalence of >37.7 million individuals globally. The epidemiology of HF is highly variable across the world, with the lowest in sub-Saharan Africa [7-9]. The prevalence of HF in Europe appears to be 1–2% of adults [10-15]. Its incidence is about 5/1000 person-years in adults [1,16,17].

The highly increasing incidence of HF in the USA since the 1970s has been described as an epidemic [18-20]. An estimated 6 million American adults ≥20 years of age had HF. Prevalence is higher in women than men ≥80 years of age; overall prevalence is especially high in both Black females and Black males [8,9].
In Asia and Africa, especially north Africa where our study was conducted, there are a limited number of reports regarding the prevalence of HF. In Japan, it is estimated that 1.0 million individuals have HF [21,22]. In China, HF affects 4.2 million individuals with 500.000 new cases diagnosed every year [23,24].

The Prevalence of HF risk factors also varies worldwide, with hypertension being most common in Latin America, the Caribbean, Eastern Europe, and sub-Saharan Africa. Our study showed that HTN and DM are the main risk factors leading to Cardiovascular disease (CVD), especially HF.

Ischemic heart disease (HD) is most prevalent in Europe and North America. Valvular HD is more common in East Asia and Asia-Pacific countries [8,9].

Concerning our population, formerly dominated by the valvular HD, ischemic HD is becoming the first cause of HF. Our study confirms these findings.

It is generally believed that, of those with HF, about 50% have HFrEF and 50% have HFpEF/HFmrEF, mainly based on studies in hospitalized patients [1][25-28]. That was the case in our study with 48.9% having HFrEF and 51.1% separated between patients with HFpEF and HFmrEF.

Conclusion:-
Heart failure is a major public health problem that represents a challenge for the organization of medical care systems. Ischemic heart disease is the main etiology. The frequency and severity of this disease must encourage us to treat our patients as best we can, making the most of our resources and explaining in detail to patients the merits of each therapy. This should also encourage us to develop management structures such as a day hospital or specialized consultations to improve the prognosis of this severe pathology.

Consent:
The authors confirm that written consent for submission and publication of this case report including image(s) and associated text has been obtained from the patient.

Disclosure of Interest:
The authors declare that they have no competing interest.

Author Contributions:
All authors have contributed to the elaboration of the manuscript.

References:-
1. McDonagh Theresa A., Metra M, Adamo M, S. Gardner R, and al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure : the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2021 ; 42 : 3599-3726. doi:10.1093/eurheartj/ehab368.
2. Savarese G, Lund LH. Global public health burden of heart failure. Card Fail Rev. 2017;3:7–11.
3. Jonathan A. Bernstein. Heart Failure. Contenusynthétique d'Elsevier.2021.
4. Yancy C.W., Jessup M., Bozkurt B., et. al.: 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013; 128: pp. e240-e327
5. Gibelin P. Insuffisancecardiaque : aspects épidémiologiques, cliniques et pronostiques. EMC -Cardiologie 2018;13(2):1-12.
6. Van Riet E.E., Hoes A.W., Limburg A., Landman M.A., Van Der Hoeven H., Rutten F.H.: Prevalence of unrecognized heart failure in older persons with shortness of breath on exertion. Eur J Heart Fail 2014; 16: pp. 772-777.
7. Gerber Y., Weston S.A., Redfield M.M., Chamberlain A.M., Manemann S.M., Jiang R., et. al.: A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern Med 2015; 175: pp. 996-1004.
8. Salim S. Virani, Alvaro Alonso and al. Heart Disease and Stroke Statistics—2021 Update. Circulation. 2021;143:e254–e743.

9. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 [published correction appears in Lancet. 2020;396:1562] Lancet. 2020;396:1204–1222

10. Conrad N, Judge A, Tran J, Mohseni H, Hedgectt D, Crespiillo AP, Allison M, Hemingway H, Cledan JG, McMurray JIV, Rahimi K. Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. Lancet 2018;391:572–580.

11. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018;392:1789–1858

12. Roger VL. Epidemiology of heart failure. Circ Res 2013;113:646–659

13. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart 2007;93:1137–1146

14. Smeets M, Vaes B, Mamouris P, Van Den Akker M, Van Pottelbergh G, Goderis G, Janssens S, Aertgeerts B, Henrard S. Burden of heart failure in Flemish general practices: a registry-based study in the Intego database. BMJ Open 2019;9:e022972

15. Virani SS, Alonso A, Benjamin EJ, Bittencourt MS and al American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2020 update: a report from the American Heart Association. Circulation 2020;141:e139–e596

16. Meyer S, Brouwers FP, Voors AA, Hillege HL, de Boer RA, Gansevoort RT, van der Harst P, Rienstra M, van Gelder IC, van Veldhuisen DJ, van Gilst WH, van der Meer P. Sex differences in new-onset heart failure. Clin Res Cardiol 2015;104:342–350

17. Brouwers FP, de Boer RA, van der Harst P, Voors AA, Gansevoort RT, Bakker SJ, Hillege HL, van Veldhuisen DJ, van Gilst WH. Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. Eur Heart J 2013;34:1424–1431.

18. McCullough PA, et al. Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J. Am. Coll. Cardiol. 2002;39:60–69.

19. Roger VL. Epidemiology of heart failure. Circ. Res. 2013;113:646–659

20. Boback Ziaeian and Gregg C. Fonarow. Epidemiology and aetiology of heart failure. Nat Rev Cardiol. 2016 Jun; 13(6): 368–378.

21. Yasuhiko S, Hiroaki Sh. Epidemiology of Heart Failure in Asia. Circulation Journal. 2013;77:2209–2217

22. Okamoto H, Kitabatake A. The epidemiology of heart failure in Japan. Nihon Rinsho 2003;61:709–714 (in Japanese).[ 12. Okura Y, Ramadan MM, Ohno Y, Mitsuma W, Tanaka K, Ito M, et al. Impending epidemic: Future projection of heart failure in Japan to the year 2055. Circ J 2008;72:489–491

23. Hu Shengshou, Kong Lingzhi, editors. Report on cardiovascular diseases in China. National Center of Cardiovascular Diseases Encyclopedia of China Publishing House, 2012. 14. He J, Gu D, Wu X, [Reynolds K, Duan X, Yao C, et al. Major causes of death among men and women in China. N Engl J Med 2005; 353: 1124–1134.

24. Hu Shengshou, Kong Lingzhi, editors. Report on cardiovascular diseases in China. National Centre of Cardiovascular diseases Encyclopedia of China Publishing House, 2009.

25. van Riet EE, Hoes AW, Limburg A, Landman MA, van der Hoveen H, Rutten FH. Prevalence of unrecognized heart failure in older persons with shortness of breath on exertion. Eur J Heart Fail 2014;16:772–777.

26. Ceia F, Fonseca C, Mota T, Morais H, Matias F, de Sousa A, Oliveira A, EPICA Investigators. Prevalence of chronic heart failure in Southwestern Europe: the EPICA study. Eur J Heart Fail 2002;4:531–539

27. Bleumink GS, Knetsch AM, Sturkenboom MC, Straus SM, Hofman A, Deckers JW, Witteman JC, Stricker BH. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur Heart J 2004;25:1614–1619.

28. Koh AS, Tay WT, Teng THK, Vedin O, Benson L, Dahlstrom U, Savarese G, Lam CSP, Lund LH. A comprehensive population-based characterization of heart failure with mid-range ejection fraction. Eur J Heart Fail 2017;19:1624–1634.